Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: A cost-effectiveness analysis

Annals of Internal Medicine

Volumn 127, Issue 9, 1997, Pages 775-787

  McNamara, Robert L ^b   Lima, Joao A C ^c   Whelton, Paul K ^d   Powe, Neil R ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; HEART ATRIUM THROMBOSIS; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; STROKE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 0030681404     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-9-199711010-00001     Document Type: Article

References (58)

1. United States Agency for Health Care Policy and Research. Post-Stroke Rehabilitation Guideline Panel. Clinical practice guidelines. Rockville, MD: U.S. Department of Health and Human Services; 1995. AHCPR publication no. 92-0032.
2. Whisnant JP, Fitzgibbons JP, Kurland LT, Sayre GP. Natural history of stroke in Rochester, Minnesota, 1945 through 1954. Stroke. 1971;2:11-22.
3. Matsumoto N, Whisnant JP, Kurland LT, Okazaki H. Natural history of stroke in Rochester, Minnesota, 1955 through 1969: an extension of a previous study, 1945 through 1954. Stroke. 1973;4:20-9.
4. Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke. The Framingham study. Stroke. 1982;13:290-5.
5. Dobkin B. The economic impact of stroke. Neurology. 1995;45(2 Suppl 1): S6-9.
6. Cardiogenic brain embolism: the second report of the Cerebral Embolism Task Force. Arch Neurol. 1989;46:727-43.
7. Manning WJ, Weintraub RM, Waksmonski CA, Haering JM, Rooney PS, Maslow AD, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med. 1995;123:817-22.
8. Pop G, Sutherland GR, Koudstaal PJ, Sit TW, de Jong G, Roelandt JR. Transesophageal echocardiography in the detection of intracardiac embolic sources in patients with transient ischemic attacks. Stroke. 1990;21:560-5.
9. Hofmann T, Kasper W, Meinertz T, Geibel A, Just H. Echocardiographic evaluation of patients with clinically suspected arterial emboli. Lancet. 1990; 336:1421-4.
10. Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesophageal echocardiography in detecting cardiac sources of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol. 1991;17:66-72.
11. Cujec B, Polasek P, Voll C, Shuaib A. Transesophageal echocardiography in the detection of potential cardiac source of embolism in stroke patients. Stroke. 1991;22:727-33.
12. de Beider MA, Lovat LB, Tourikis L, Leech G, Camm AJ. Limitations of transesophageal echocardiography in patients with focal cerebral ischaemic events. Br Heart J. 1992;67:297-303.
13. Shyu KG, Chen JJ, Huang ZS, Hwang JJ, Lee TK, Kuan P, et al. Role of transesophageal echocardiography in the diagnostic assessment of cardiac sources of embolism in patients with acute ischemic stroke. Cardiology. 1994; 85:53-60.
14. Leung DY, Black IW, Cranney GB, Walsh WF, Grimm RA, Stewart WJ, et al. Selection of patients for transesophageal echocardiography after stroke and systemic embolic events. Role of transthoracic echocardiography. Stroke. 1995;26:1820-4.
15. Amarenco P, Duyckaerts C, Tzourio C, Henin D, Bousser M, Hauw J. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med. 1992;326:221-5.
16. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med. 1996;334:1216-21.
17. Comess KA, DeRook FA, Beach KW, Lytyl NJ, Golby AJ, Albers GW. Transesophageal echocardiography and carotid ultrasound in patients with cerebral ischemia: prevalence of findings and recurrent stroke risk. J Am Coll Cardiol. 1994;23:1598-603.
18. Matchar DB, McCrory DC, Barnett HJ, Feussner JR. Medical treatment for stroke prevention. Ann Intern Med. 1994;121:41-53.
19. DeRook FA, Comess KA, Albers GW, Popp RL. Transesophageal echocardiography in the evaluation of stroke. Ann Intern Med. 1992;117:922-32.
20. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
21. Jones EF, Donnan GA, Calafiore P, Tonkin AM. Transoesophageal echocardiography in the investigation of stroke: experience in 135 patients with cerebral ischaemic events. Aust N Z J Med. 1993;23:477-83.
22. Labovitz AJ, Camp A, Castello R, Martin TJ, Ofili EO, Rickmeyer N, et al. Usefulness of transesophageal echocardiography in unexplained cerebral ischemia. Am J Cardiol. 1993;72:1448-52.
23. Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. Stroke. 1983;14:677-81.
24. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-11.
25. Magar RS, Doucette D, Kassam R, Seto W, Einarson TR. Warfarin in atrial fibrillation: a meta-analysis and pharmacologic analysis. Canadian Journal of Clinical Pharmacology. 1995;2:109-17.
26. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-12.
27. Eckman MH, Levine HJ, Pauker SG. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest. 1992;102(4 Suppl):538S-49S.
28. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144-52.
29. Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR. Determinants of early recurrence of cerebral infarction: The Stroke Data Bank. Stroke. 1989;20:983-9.
30. Dahl T, Abildgaard U, Sandset PM. Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit? J Intern Med. 1995;237:323-9.
31. Persson U, Silverberg R, Lindgren B, Norrving B, Jadback G, Johansson B, et al. Direct costs of stroke for a Swedish population. Int J Technol Assess Health Care. 1990;6:125-37.
32. Terent A, Marke L, Asplund K, Norrving B, Jonsson E, Wester P. Costs of stroke in Sweden: a national perspective. Stroke. 1994;25:2363-9.
33. Bowen J, Yaste C. Effect of a stroke protocol on hospital costs of stroke patients. Neurology. 1994;44:1961-4.
34. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease. Am J Cardiol. 1996;78:409-14.
35. Lee AJ, Huber J, Stason WB. Poststroke rehabilitation in older Americans. The Medicare experience. Med Care. 1996;34:811-25.
36. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke. 1994;25:1149-56.
37. Mills E, Thompson M. The economic costs of stroke in Massachusetts. N Engl J Med. 1978;299:415-8.
38. Office of National Health Statistics. DRI/McGraw Hill HCC, 4th Qrt 1995.
39. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
40. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke. 1994;25:1721-5.
41. Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care. 1987;25:25-34.
42. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA. 1992;267: 2055-61.
43. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease. Part II: Preventive therapies. Prog Cardiovasc Dis. 1995;37:243-71.
44. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease. Part III. Ischemia, congestive heart failure, and arrhythmias. Prog Cardiovasc Dis. 1995;37:307-46.
45. Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol. 1997;29:122-30.
46. Fatkin D, Scalia G, Jacobs N, Burstow D, Leung D, Walsh W, et al. Accuracy of biplane echocardiography in detecting left atrial thrombus. Am J Cardiol. 1996;77:321-3.
47. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992;305:1457-60.
48. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-45.
49. Sansoy V, Abbott RD, Jayaweera AR, Kaul S. Low yield of transthoracic echocardiography for cardiac source of embolism. Am J Cardiol. 1995;75: 166-9.
50. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993;118:511-20.
51. Matchar DB, Pauker SG. Endarterectomy in carotid disease. A decision analysis. JAMA. 1987;258:793-8.
52. Carotid surgery versus medical therapy in asymptomatic carotid stenosis. The CASANOVA Study Group. Stroke. 1991;22:1229-35.
53. Nagli IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making. 1992;12:239-49.
54. Desbiens NA. Should all patients with atrial fibrillation be screened with echocardiography? J Gen Intern Med. 1992;7:131-9.
55. Bombadier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL. Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med. 1986;81:565-78.
56. Kestle J, Levine M, Depauw S, Kelleher L. A time trade off method for measuring quality of life in stage 2 breast cancer patients [Abstract]. Clin Res. 1989;37:316A.
57. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Canadian Erythropoietin Study Group. BMJ. 1990;300:573-8.
58. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-5.